Home | Contact us | Disclaimer
Dr. Tony Cruz
Chief Executive Officer

Dr. Cruz is one of the founders of Transition Therapeutics and has held the position of Chief Executive Officer of Transition Therapeutics since its inception in July 1998. Dr. Cruz was a Co-Founder, Vice-President and Director at Angiotech Pharmaceuticals Inc. Dr. Cruz has been a Senior Scientist at Mount Sinai Hospital since 1995 and was the CEO and President of the Canadian Arthritis Network until 2001. He has also served as a consultant for biotechnology companies and investment firms.
Carl Damiani
Chief Operating Officer

Mr. Damiani holds a broad leadership role in overseeing Transition employees and activities in Toronto, San Francisco and Ireland, as well as in the operations and advancement of the current development programs. Since joining Transition in 2003, Mr. Damiani has held the roles of Vice-President of Business Development and Director of Business Development.
Nicole Rusaw
Chief Financial Officer

Ms. Rusaw has been with the Company since 2005 and was appointed as Chief Financial Officer in December 2011. While at Transition, Ms. Rusaw has been responsible for a broad range of activities with a focus on financial reporting and regulatory compliance as well as involvement in various equity financings and strategic acquisitions.
Dr. Aleksandra Pastrak
Vice President, Clinical Development and Medical Officer

Dr. Pastrak has been with Transition since 1999 and served as VP, Research since 2005 until she was appointed VP, Clinical Development in 2011. With her expertise in medicine and pharmacology, she has made an invaluable contribution to the development of our clinical programs for various therapeutic products. Dr. Pastrak holds an MD from the School of Medicine at the University of Belgrade and M.Sc. and Ph.D. degrees in Clinical Pharmacology from the University of Toronto.
Dr. Bruce Connop
Vice President, Non-Clinical & Pharmaceutical Development

Dr. Connop has been with Transition since 2006 and served as Sr. Director, Nonclinical Drug Development until he was appointed VP, Non-Clinical & Pharmaceutical Development in 2012. With his expertise in pharmacology, toxicology and manufacturing he is responsible for a broad range of activities and has made significant contributions to the advancement of pipeline products. Dr. Connop holds a Ph.D. from Queen’s University and has had experience at other biotech and pharmaceutical companies .
© 2013 Transition Therapeutics Inc.